Cochrane Review Group
Metabolic and Endocrine Disorders
84 systematic reviews in Metabolic and Endocrine Disorders ask 1,105 questions. 39.3% have no studies to answer them, 22.3% rest on very low certainty evidence and 14.1% reach moderate or high certainty.
Reviews
84
Questions
1,105
current versions
No studies
39.3%
Moderate or high
14.1%
No studies 434 · 39.3%Ungraded 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Health‐related quality of life · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Sexual quality of life · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Treatment withdrawal due to adverse events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | RR 1.04 [0.58, 1.86] | 2 studies · 122 participants | Very low |
Testosterone vs placebo Prostate‐related events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Lower urinary tract symptoms · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Erectile function · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Testosterone vs PDE5I Sexual quality of life · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Testosterone vs PDE5I Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Treatment withdrawal due to adverse events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 84
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
CochraneSoF table
16 questions
Intraoperative neuromonitoring versus visual nerve identification for prevention of recurrent laryngeal nerve injury in adults undergoing thyroid surgery
CochraneSoF table
7 questions
First aid glucose administration routes for symptomatic hypoglycaemia
CochraneSoF table
20 questions
Oral vitamin B₁₂ versus intramuscular vitamin B₁₂ for vitamin B₁₂ deficiency
CochraneSoF table
6 questions
Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus
CochraneSoF table
14 questions
Sliding scale insulin for non‐critically ill hospitalised adults with diabetes mellitus
CochraneSoF table
7 questions
Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for adrenal tumours in adults
CochraneSoF table
5 questions
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia
CochraneSoF table
43 questions
Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes mellitus
CochraneSoF table
7 questions
Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus
CochraneSoF table
21 questions
Psychological interventions for diabetes‐related distress in adults with type 2 diabetes mellitus
CochraneSoF table
7 questions
Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
CochraneSoF table
14 questions
Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years
CochraneSoF table
6 questions
Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years
CochraneSoF table
6 questions
Insulin monotherapy compared with the addition of oral glucose‐lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control
CochraneSoF table
35 questions
Supportive interventions for enhancing dietary intake in malnourished or nutritionally at‐risk adults
CochraneSoF table
7 questions
Radioiodine therapy versus antithyroid medications for Graves' disease
CochraneSoF table
7 questions
Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis
CochraneSoF table
14 questions
Self management interventions for type 2 diabetes in adult people with severe mental illness
CochraneSoF table
7 questions
Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years
CochraneSoF table
14 questions
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
CochraneSoF table
14 questions
Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus
CochraneSoF table
7 questions
Drug interventions for the treatment of obesity in children and adolescents
CochraneSoF table
6 questions
Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance
CochraneSoF table
6 questions
Total or near‐total thyroidectomy versus subtotal thyroidectomy for multinodular non‐toxic goitre in adults
CochraneSoF table
6 questions